TLCGets US Go-Ahead For Abelcet
The Liposome Company has been granted approval for Abelcet (amphotericin B lipid complex), for the treatment of aspergillosis in patients refractory to conventional therapy, in the USA. This is the first domestic approval for the firm, although Abelcet has been approved for marketing in the UK, Spain and Luxembourg.
Charles Baker, chairman and chief executive of TLC, said that the firm plans to market Abelcet directly with its salesforce of 20 representatives. Shipping to wholesalers will begin in December, and the product should be launched to physicians in the New Year. Abelcet overcomes some of the limitations of conventional amphotericin B treatment of aspergillosis, such as nephrotoxicity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze